Gupta Ranjan, Kim Jp, Spiegel Jack, Ferguson Steven M
Per Med. 2004 Dec 1;1(1):115-124. doi: 10.1517/17410541.1.1.115.
For innovators at academic or industrial institutions to develop personalized medicine products at the accelerated pace required, rapid access to state-of-the-art research tools and reagents are needed. Unreasonable restrictions or delays in the use of such tools may undermine the development of these customized diagnostics and therapeutic products designed to provide significant treatment benefits to patients who frequently do not benefit from traditional therapeutic approaches. In its funding agreements and its own internal research programs, the National Institutes of Health is implementing policies to facilitate the exchanges of these research tools and related resources.
对于学术机构或产业机构的创新者而言，要以所需的加速步伐开发个性化医疗产品，就需要快速获取最先进的研究工具和试剂。对这类工具使用的不合理限制或延迟，可能会破坏这些定制化诊断和治疗产品的开发，而这些产品旨在为那些常常无法从传统治疗方法中受益的患者提供显著的治疗益处。美国国立卫生研究院在其资助协议和自身内部研究项目中，正在实施各项政策以促进这些研究工具及相关资源的交流。
